Retatrutide represents the frontier of incretin-based metabolic research — the first triple GIP/GLP-1/glucagon receptor agonist to reach Phase 3 clinical trials. The TRIUMPH-2 readout of 24.2% weight reduction at 48 weeks establishes it as the most potent metabolic intervention ever evaluated.
What is Retatrutide?
Retatrutide (LY3437943) is a synthetic 40-amino-acid peptide engineered by Eli Lilly as a co-agonist of three receptors: GIP, GLP-1, and glucagon. Its triple agonist mechanism distinguishes it from both the pure GLP-1 agonists (semaglutide) and the dual GIP/GLP-1 agonists (tirzepatide), by adding glucagon receptor activation — which drives increased energy expenditure through thermogenesis.
Mechanism of Action
GIP Receptor — Adipose and Appetite
GIP receptor activation enhances adipose tissue metabolic buffering, improves lipid handling, and contributes to central appetite regulation. Unlike native GIP's relatively short half-life, Retatrutide's engineered structure provides sustained GIPR agonism with an approximately 6-day half-life.
GLP-1 Receptor — Satiety and Insulin
GLP-1 receptor activation drives glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite suppression. The GLP-1 component is the primary satiety driver in all three incretin classes (semaglutide → tirzepatide → retatrutide).
Glucagon Receptor — Energy Expenditure
Glucagon receptor activation differentiates Retatrutide from earlier incretins. Glucagon agonism stimulates hepatic fatty acid oxidation and ketogenesis, increases brown adipose tissue thermogenesis, and upregulates energy expenditure. This additional mechanism is believed to account for the incremental weight reduction over dual-agonist tirzepatide.
TRIUMPH-2 Clinical Data
- Weight Reduction: 24.2% at 48 weeks (8 mg/week) — highest in any Phase 3 metabolic trial.
- Rapid Onset: Mean double-digit weight loss by week 24 — faster than semaglutide or tirzepatide.
- Cardiometabolic: Significant HbA1c reduction, improved lipids, favourable body composition changes.
This article is for scientific and educational purposes only. Retatrutide is available exclusively for laboratory research purposes.
Element42 Peptides — Australian owned, third-party tested. View Retatrutide product page.